Laxmi Organic Industries Q1 FY27: Revenue Up 40%, EBITDA Surges 272% – Key Takeaways from the Earnings Call

Laxmi Organic Industries Limited (NSE: LXCHEM, BSE: 543277) hosted its Q1 FY27 earnings conference call on 30 July 2026, led by Managing Director & CEO Dr. Rajan Venkatesh and new CFO Amit Jain. Here’s a breakdown of the numbers and the key management commentary from the Q&A session.

Key Financial Highlights

Essentials delivered an EBITDA margin of 11-12%, a sharp turnaround from the low single digits a year ago, driven by roughly 10% volume growth at the enterprise level, better price realization, and procurement/supply-chain efficiencies that helped offset higher freight and energy costs.

Dahej Project: Capex and Ramp-Up Timeline

Management clarified the Dahej capex phasing in response to analyst questions:

• Phase 1 (already capitalized): accounted for roughly 15-18% of total project capex, and is backed by a multi-year contract with a large global MNC customer.
• Phase 2: 85% of the remaining capex will be capitalized in Q2 FY27. The project is split 60% specialty / 40% Essentials.
• Full-year capex guidance (including Dahej): Rs. 125-150 crore.
• Timeline: mechanical completion and stabilization through Q2-Q3 FY27, customer qualification in Q3, and ramp-up starting Q4 FY27 continuing into FY28-FY29.
• Incremental depreciation from Phase 2 capitalization: approximately Rs. 7-7.5 crore per quarter starting next quarter.
• Debt: term debt has peaked at ~Rs. 610 crore (net debt/equity ~0.3x); repayment is expected to begin next financial year and continue over five years.

Margin Outlook: Management’s Cycle-Based Framework

Asked directly whether the improved margins are sustainable, Rajan Venkatesh framed both businesses on a multi-year, cycle-based lens rather than a quarterly one:

• Essentials: While Q1 FY27 saw an 11-12% EBITDA margin — a sharp swing from the pressured margins of Q3 FY26 — management expects the business to average out to a mid-single-digit EBITDA margin over the cycle, given feedstocks that reprice daily/weekly. Ethyl acetate spreads were noted to be running above the 12-year average of $215-220 through March-April.
• Specialty: Margins were pressured through FY25-26 by the phase-out of one product (10% of specialty revenue) and a ~25% deflationary move in feedstock costs. Management is targeting a return toward the 20-25% margin range achieved previously, though not necessarily in the near term given new Dahej capacity is still ramping up. Specialty is a batch-process, campaign-driven business, and management asked analysts to judge it over a 2-3 year window rather than quarter to quarter.

Other Growth Projects

• Project Vaayu (the Hitachi-linked project): mechanical completion expected early Q3 FY27, with meaningful revenue contribution flowing from FY28.
• Electrochemical fluorination: Laxmi describes itself as the first mover in India and says it retains a leadership position, with partnership announcements expected “in due course.” Fluorination made a partial revenue contribution in Q1, limited in part by delayed monsoons.
• Ethyl acetate capacity at the Lote site has been commissioned at world scale, timed to capture current demand.
• Diketene derivatives: Laxmi is doubling capacity in this segment as it moves to become the world’s #3 producer, aiming to deepen penetration with existing and new customers.

Macro and Raw Material Backdrop

Management described Q1 as dominated by volatility linked to the West Asia crisis (intensifying late February through April, easing later in the quarter, with a “2.0” version emerging in Q2), alongside structural capacity restructuring in Europe, Japan, and Korea. Key feedstocks like acetic acid and methanol spiked sharply off a March base before moderating into May-June, while shipping disruptions (Red Sea, Gulf of Hormuz, a South China typhoon) added further pressure on logistics and buyer behaviour — with downstream customers responding with a mix of overstocking, just-in-time buying, and deferment.

Segment demand snapshot: Pharma Solutions and Agro Solutions were broadly stable; Pigments saw some softness; Printing & Packaging held steady; Industrial Solutions (coatings and newer-age industries) showed positive momentum. Acetic anhydride demand from the pharmaceutical sector, muted since its COVID-era peak, is showing renewed positive momentum.

A planned turnaround at the company’s Site 1 was completed safely in the second half of May.

This article is based on Laxmi Organic Industries Limited’s Q1 FY27 earnings call transcript filed with the stock exchanges. It is intended for informational purposes only and does not constitute investment advice. Readers are advised to consult a qualified financial advisor before making any investment decisions.